The overactive bladder in children: A potential future indication for tolterodine

BJU International

Volumn 87, Issue 6, 2001, Pages 569-574

  Hjalmas K ^a   Hellstrom A L ^a   Mogren, K ^a   Lackgren G ^b   Stenberg, A ^b  

^a QUEEN SILVIA CHILDREN'S HOSPITAL   (Sweden)

^b UNIVERSITY CHILDREN S HOSPITAL   (Sweden)

Author keywords

Antimuscarinic agents; Children; Dose finding study; Overactive bladder; Tolterodine

Indexed keywords

TOLTERODINE;

ARTICLE; BLADDER DISEASE; CHILD; CLINICAL ARTICLE; DETRUSOR DYSSYNERGIA; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG INDICATION; DRUG METABOLISM; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; MALE; MICTURITION; PRIORITY JOURNAL; RESIDUAL URINE; URINE INCONTINENCE;

ADMINISTRATION, ORAL; BENZHYDRYL COMPOUNDS; CHILD; CHILD, PRESCHOOL; CRESOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MUSCARINIC ANTAGONISTS; PHENYLPROPANOLAMINE; URINARY INCONTINENCE;

EID: 0035072202     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.2001.00084.x     Document Type: Article

References (29)

1. Current concepts in the treatment of disorders of micturition
2. Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability
3. Oxybutynin. The clinical experience
4. Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: Oxybutynin versus propantheline versus placebo
5. Pharmacokinetics and clinical effects of oxybutynin in geriatric patients
6. Anticholinergic therapy: The need for continued surveillance
7. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: A pooled analysis
8. Tolterodine, a new antimuscarinic agent: As effective but better tolerated than oxybutynin in patients with an overactive bladder
9. Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity
10. Tolterodine - A new bladder-selective antimuscarinic agent
11. Tissue distribution of tolterodine and its metabolites: Low penetration into the central nervous system
12. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder
13. Identification of medications that cause cognitive impairment in older people: The case of oxybutynin chloride
14. Electrophysiological evaluation of potential adverse effects of tolterodine, oxybutynin and trospium chloride on the central nervous system
15. Tolterodine: Selectivity for the bladder over effects on visual accommodation
16. Determination of tolterodine and the 5-hydroxymethyl metabolite in plasma, serum and urine using gas chromatography-mass spectrometry
17. Serum protein binding of tolterodine and its major metabolites in humans and several animal species
18. Implications of altered plasma protein binding in disease states
19. Adverse effects of oxybutynin chloride in pediatrics
20. Incontinence
21. Intravesical oxybutynin for neurogenic bladder dysfunction: Less systemic side effects due to reduced first pass metabolism
22. Expanded followup of intravesical oxybutynin chloride use in children with neurogenic bladder
23. Complications of intravesical oxybutynin chloride therapy in the pediatric myelomeningocele population
24. The influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamics of tolterodine
25. Food increases the bioavailability of tolterodine, but not effective exposure
26. Efficacy and safety of tolterodine in patients with detrusor instability: A dose-ranging study
27. Dose-ranging study of tolterodine in patients with detrusor hyperreflexia
28. Tolterodine in the treatment of overactive bladder: Analysis of the pooled phase II efficacy and safety data
29. Efficacy and tolerability of tolterodine in children with detrusor hyperreflexia